Skip to main content
Premium Trial:

Request an Annual Quote

Gene-IT Weighs its Options as it Seeks to Enter US Market and Accelerate Growth


With nine customers in Europe since its launch in 1998, Gene-IT, based near Paris, France, is ready to launch an aggressive campaign to target the US market. But Jean-Jacques Codani, CEO of Gene-IT, said the company is still “exploring its options” for the best way to do so.

Codani said Gene-IT is considering partnering with a US company as well as forming strategic alliances with American universities in order to gain entry into the market. Another option is to open a US office. While the company has already signed a deal with DuPont of Wilmington, Del., and has several prospective US customers in the pipeline, Codani said a physical presence in the US would support the science-based approach the company takes with its customers.

“We don’t want to be the bioinformatics salesman of the week showing up at customers’ doors,” Codani said.

Gene-IT’s flagship product, LASSAP, requires a bit of education on the part of the customer, said Henk Heus, director of bioinformatics applications. He said Gene-IT’s approach is similar to that of GCG’s in its focus on being “a technology company, not a marketing company.” Thus, a full scientific team in the US would be preferable to a few sales representatives, Heus said.

LASSAP is a large-scale sequence comparison tool that is capable of comparing entire sequence databases. It uses a set of classical sequence comparison algorithms, such as Blast, Smith-Waterman, and Needleman-Wunsch, that have been optimized and scaled by Gene-IT to work on parallel systems. These algorithms, as well as others proprietary to Gene-IT, use the same sequence database format as the database management and query system. Because the output from each algorithm is unified, the results can be queried, stored, and analyzed in a streamlined manner, Codani said.

Codani said the system offers similar performance to dedicated bioinformatics hardware accelerators, but also provides the software flexibility that dedicated boxes lack.

Gene-IT currently has LASSAP software contracts with BioMérieux, DuPont, Genoscope, Infobiogen, Organon, and the Pasteur Institute. In addition, Gene-IT outsources its LASSAP-based bioinformatics infrastructure to Derwent and Servier Labs and is involved in scientific collaboration programs with the European Bioinformatics Institute and the French Myopathy Association/French National Center for Scientific Research. Codani said that a subsidiary of a large agricultural company has recently signed on for a trial license.

Codani said Gene-IT’s short-term plans include increasing its sales to large biotech and pharmaceutical customers. In the mid-term, the company will scale up its business model to meet the needs of an estimated 2,000 potential licensees among smaller biotechs and labs.

The company hopes to have a substantial US presence in place by 2002. “We’re confident if we move intelligently we can sell in this market,” said Codani.

— BT

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.